Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Izumerogant - Immunic

Next Previous
Drug Profile

Izumerogant - Immunic

Alternative Names: IMU-935

Latest Information Update: 01 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4SC
  • Developer Immunic
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Graft-versus-host disease; Guillain-Barre syndrome; Inflammatory bowel diseases; Prostate cancer; Psoriasis

Most Recent Events

  • 17 Apr 2023 Discontinued - Phase-I for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in United Kingdom (PO) (Immunic pipeline, April 2023)
  • 17 Apr 2023 Discontinued - Phase-I for Psoriasis in Australia, New Zealand, Macedonia, Bulgaria (PO) (Immunic pipeline, April 2023)
  • 17 Apr 2023 Discontinued - Preclinical for Autoimmune disorders in Germany (PO) (Immunic pipeline, April 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top